Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate). The multi-center study consists of an open label safety component followed by a randomized, double-blind, placebo-controlled study that will enroll approximately 140 patients with episodic hepatic encephalopathy in the US and Eastern Europe. The primary efficacy measure will be the proportion of patients who exhibit a hepatic encephalopathy episode during the four-month treatment period.